CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4(+) CAR T-cell antitumor activity.
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4(+) CAR T-cell antitumor activity.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CD4+ T细胞和CD4+嵌合抗原受体(CAR)T细胞在临床前模型和患者中显示出高度可变的抗肿瘤活性;然而,决定CD4+ T细胞如何以及何时促进肿瘤消退的机制尚不完全清楚。借助功能性活体成像,我们报告,干扰素(IFN)-的产生而非穿孔素介导的细胞毒性是抗CD19 CD4+ CAR-T 细胞消除肿瘤的主要机制。在机制上,小鼠或人CD4+ CAR-T 细胞衍生的IFN-广泛扩散,远距离作用于肿瘤细胞,选择性杀伤对细胞因子诱导的凋亡敏感的肿瘤,包括抗原阴性变异体。在接受抗CD19 CAR-T 细胞治疗且CAR CD4:CD8比值升高的患者中,血清IFN-的强烈诱导与生存期增加相关。我们提出,肿瘤细胞对IFN-促凋亡活性的敏感性是CD4+ CAR-T 细胞疗效的主要决定因素,并可考虑用于指导免疫治疗期间CD4+ T细胞的使用。
CD4 + T cells and CD4 + chimeric antigen receptor (CAR) T cells display highly variable antitumor activity in preclinical models and in patients; however, the mechanisms dictating how and when CD4 + T cells promote tumor regression are incompletely understood. With the help of functional intravital imaging, we report that interferon (IFN)- production but not perforin-mediated cytotoxicity was the dominant mechanism for tumor elimination by anti-CD19 CD4 + CAR T cells.
Mechanistically, mouse or human CD4 + CAR T-cell-derived IFN- diffused extensively to act on tumor cells at distance selectively killing tumors sensitive to cytokine-induced apoptosis, including antigen-negative variants. In anti-CD19 CAR T-cell-treated patients exhibiting elevated CAR CD4:CD8 ratios, strong induction of serum IFN- was associated with increased survival.
We propose that the sensitivity of tumor cells to the pro-apoptotic activity of IFN- is a major determinant of CD4 + CAR T-cell efficacy and may be considered to guide the use of CD4 + T cells during immunotherapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。